Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space

Cytokinetics (NASDAQ:CYTK) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 4, B. Riley initiated coverage of Cytokinetics (NASDAQ:CYTK) with a Buy rating and a $108 price target. The positive stance underscores the research firm’s confidence about the company’s ability to capture market share in the cardiac myosin inhibitor space.

The company has already started flexing its muscles in the space with Myqorzo, its candidate drug approved by the US Food and Drug Administration for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). According to B.Riley, the company’s competitive edge stems from its candidate drug’s “materially streamlined REMS” compared to Bristol Myers Squibb’s CAMZYOS.

Launched at the start of the year, Myqorzo has zero drug-drug interaction pharmacy recalls , more flexible echo windows, and faster dose stabilization. While there are about 11,000 active CAMZYOS patients, higher attrition rates suggest a sizable 5K churned patients that Cytokinetics can target with its drug.

On January 28, Barclays initiated coverage of the stock with an Overweight rating and an $87 price target. The investment bank has touted the company’s prospects following the launch of Myqorzo, a differentiated label that reduces the need for echocardiogram monitoring.

Cytokinetics, Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle-directed medicines to treat serious diseases, particularly those affecting cardiovascular and neuromuscular function. Founded in 1997, the company specializes in muscle biology to develop small-molecule compounds that act as either activators or inhibitors to improve muscle function.

While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Stocks to Buy and Hold for the Next 6 Months and 11 Best High Return Penny Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.